<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03987074</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-454-5533</org_study_id>
    <nct_id>NCT03987074</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Adults With Nonalcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of study
      drug(s) in adults with nonalcoholic steatohepatitis (NASH).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 29, 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experience Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Any Grade ≥ 1 Laboratory Abnormality</measure>
    <time_frame>First dose date up to Week 24 plus 30 days</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Semaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Semaglutide 0.24 mg - 2.4 mg (dose escalation every 4 weeks) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide + Firsocostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Semaglutide 0.24 mg - 2.4 mg (dose escalation every 4 weeks) + firsocostat 20 mg for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide + Cilofexor 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Semaglutide 0.24 mg - 2.4 mg (dose escalation every 4 weeks) + cilofexor 30 mg for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide + Cilofexor 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Semaglutide 0.24 mg - 2.4 mg (dose escalation every 4 weeks) + cilofexor 100 mg for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide + Firsocostat + Cilofexor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Semaglutide 0.24 mg - 2.4 mg (dose escalation every 4 weeks) + firsocostat 20 mg + cilofexor 30 mg for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide</intervention_name>
    <description>Solution for injection administered subcutaneously once weekly</description>
    <arm_group_label>Semaglutide</arm_group_label>
    <arm_group_label>Semaglutide + Cilofexor 100 mg</arm_group_label>
    <arm_group_label>Semaglutide + Cilofexor 30 mg</arm_group_label>
    <arm_group_label>Semaglutide + Firsocostat</arm_group_label>
    <arm_group_label>Semaglutide + Firsocostat + Cilofexor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Firsocostat</intervention_name>
    <description>Tablets administered orally once daily</description>
    <arm_group_label>Semaglutide + Firsocostat</arm_group_label>
    <arm_group_label>Semaglutide + Firsocostat + Cilofexor</arm_group_label>
    <other_name>GS-0976</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilofexor</intervention_name>
    <description>Tablets administered orally once daily</description>
    <arm_group_label>Semaglutide + Cilofexor 100 mg</arm_group_label>
    <arm_group_label>Semaglutide + Cilofexor 30 mg</arm_group_label>
    <arm_group_label>Semaglutide + Firsocostat + Cilofexor</arm_group_label>
    <other_name>GS-9674</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Historical liver biopsy consistent with NASH with stage 2-3 fibrosis according to NASH
             Clinical Research Network (CRN) classification OR clinical diagnosis of nonalcoholic
             fatty liver disease and screening FibroTest, magnetic resonance imaging - proton
             density fat fraction (MRI-PDFF), and FibroScan

          -  Screening laboratory parameters, as determined by central laboratory:

               -  Alanine aminotransferase (ALT) ≤ 5 x upper limit of the normal range (ULN)

               -  Estimated glomerular filtration rate (eGFR) ≥ 30 milliliter/minute (mL/min), as
                  calculated by the Modification of Diet in Renal Disease (MDRD) study equation

               -  HbA1c ≤ 9.5%

               -  International normalized ratio (INR) ≤ 1.2, unless due to therapeutic
                  anti-coagulation therapy

               -  Platelet count ≥ 100,000/μL

               -  Total bilirubin &lt; 1.3 x ULN unless alternate etiology such as Gilbert's syndrome
                  present

               -  Calcitonin ≤ 100 ng/L

          -  Body Mass Index (BMI) &gt; 23 kg/m^2 and body weight of &gt; 60 kg

        Key Exclusion Criteria:

          -  Any historical liver biopsy consistent with cirrhosis

          -  Any history of decompensated liver disease, including ascites, hepatic encephalopathy,
             or variceal bleeding

          -  Other causes of liver disease, including but not limited to: alcoholic liver disease,
             hepatitis B, hepatitis C, autoimmune disorders (eg, primary biliary cholangitis (PBC),
             primary sclerosing cholangitis (PSC), autoimmune hepatitis), drug-induced
             hepatotoxicity, Wilson disease, clinically significant iron overload, or
             alpha-1-antitrypsin deficiency requiring treatment

          -  History of liver transplantation

          -  History of hepatocellular carcinoma

          -  History of pancreatitis (acute or chronic)

          -  Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or
             medullary thyroid carcinoma

          -  Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA) in the period from
             90 days prior to the date of the Screening Visit

          -  Individuals on antidiabetic medications must be on a stable dose for at least 90 days
             prior to the date of the Screening Visit and in the period between the date of the
             Screening Visit and Enrollment (Day -14)

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Liver Health - Arizona Liver Health</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Research Centers</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego (UCSD)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruane Clinical Research Group, Inc</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Empire Clinical Trials, LLC</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Associates Research Group</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schiff Center for Liver Diseases - University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Specialists of Georgia</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jubilee Clinical Research, Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro One</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Gastroenterology</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro One</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Medical Research, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Clinical Research Institute</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Liver Institute at Methodist Dallas Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Research Corporation</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Institute of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 12, 2019</study_first_submitted>
  <study_first_submitted_qc>June 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2019</study_first_posted>
  <last_update_submitted>December 17, 2019</last_update_submitted>
  <last_update_submitted_qc>December 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Firsocostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

